Table 9. Niraparib as monotherapy and in combination therapy.

PFS: progression-free survival; OS: overall survival; ORR: objective response rate; BRCA: breast cancer-associated; ATM: ataxia-telangiectasia mutated; PALB2: partner and localizer of BRCA2; HRD: homologous recombination deficiency

Clinical trial	Phase	N	Study objective	Germline mutations	Somatic mutations	PFS	OS	ORR
Niraparib monotherapy
NCT03601923 [57]	II		Proof-of-concept trial evaluating niraparib in patients with HRD pancreatic cancer progressed on one line of therapy except platinum agents	Germline and somatic mutations in BRCA1, BRCA2, PALB2, CHEK2, or ATM		Currently enrolling
NCT03553004 NIRA-PANC [58]	II		Efficacy in metastatic pancreatic cancer patients with HRD mutations who received at least one prior line of therapy.	Germline and somatic HRD mutations		Currently enrolling
Niraparib with immunotherapy
NCT03404960 Parpvax [59]	Ib/II		Study of niraparib plus either ipilimumab or nivolumab in patients with advanced pancreatic cancer whose disease has not progressed on platinum-based therapy	HRD will be identified after enrollment		Currently enrolling.